Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury

Cilostazol increases intracellular cyclic adenosine monophosphate (cyclic AMP) levels by inhibiting type III phosphodiesterase. It was approved by the Food and Drug Administration for the treatment of intermittent claudication. Its principal actions include inhibition of platelet aggregation, antith...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:CNS Neurosci Ther
Prif Awduron: Lee, Jeong Hyun, Park, So Youn, Shin, Hwa Kyoung, Kim, Chi Dae, Lee, Won Suk, Hong, Ki Whan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Publishing Inc 2008
Pynciau:
Review
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494013/
https://ncbi.nlm.nih.gov/pubmed/18482026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1527-3458.2008.00042.x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg